Eptifibatide is a cyclic heptapeptide that reversibly inhibits platelet aggregation by binding to a GP-IIb/IIIa receptor site on platelets. Eptifibatide is produced by using a method based on solid phase peptide synthesis technology. The crude material thus produced is purified by RP-HPLC and characterized by polarimetry, amino acid analysis, NMR, MALDI-TOF, LC-MS, Ion chromatography and platelet aggregation assay for biological activity.

We are now synthesizing Eptifibatide in a cGMP compliant facility. The indigenously developed Eptifibatide is marketed in the Indian market under the brand name ‘CoroMax’.

Disclaimer: Products under patents are offered for sale only in those countries where patents have expired.